control dmso  (Gold Biotechnology Inc)

Journal: bioRxiv

Article Title: Predictable clonal hierarchies from restricted progenitors provide a framework for cell type-specific therapies in glioblastoma

doi: 10.64898/2026.02.21.707071

Figure Lengend Snippet: Track-informed combination targeting of progenitor populations suppresses GBM growth a) LGALS1 expression across progenitor Tracks (left) and progenitor cell types (right) in the CellTag lineage-tracing dataset. b) FeaturePlot of LGALS1 expression in the GBM meta-atlas of primary tumor cells. c) Primary GBM meta-atlas cells were binned into LGALS1 -High (grey) and LGALS1 -Low (light blue) based on LGALS1 expression (STable6, Methods): cells were split by the median LGALS1 expression (High ≥ median, Low < median). Violin plot shows LGALS1 expression in each bin. Differential expression was then performed Low vs High (so positive avg_log2FC indicates genes enriched in LGALS1 -Low cells). Right, lollipop plot shows the top differentially expressed genes enriched in LGALS1-Low cells, highlighting CDK4 (dot size, −log10 adjusted P value; x-axis, avg_log2FC Low vs High). d) CDK4 expression across progenitor Tracks (left) and progenitor cell types (right) in the CellTag lineage-tracing dataset. e) FeaturePlot of CDK4 expression in the GBM meta-atlas of primary tumor cells. f) The combination of LGALS1 inhibition through OTX008 with CDK4 inhibition through Abemaciclib is predicted to target Track 3 progenitors (MES.Progenitor, NVP) and complementary Track 1-2 progenitors (IPC, Radial Glia). g) LGALS1 and CDK4 expression stratifies progenitor cells into complementary high-expression groups. (Top) Boxplots show LGALS1 and CDK4 expression in the CellTagging dataset comparing Progenitor vs Non-Progenitor cells. P-values are from two-sided Wilcoxon tests. (Bottom) Progenitor cells were additionally binned by global median splits of LGALS1 and CDK4 across all cells to define four mutually exclusive categories (Neither, LGALS1_high, CDK4_high, Both) and an OR category (Either_High = LGALS1_high OR CDK4_high). Lollipop plot reports the percent of progenitor cells in each category. h) Representative clones satisfying LGALS1_high or CDK4_high treatment categories across patients, as defined in panel g. Clone member cells are overlaid on the global UMAP (grey) and indicated by colored shapes, with each shape representing an individual cell within the clone. i) Representative clones multiple patients containing cells classified as Both (LGALS1_high and CDK4_high), as defined in panel g. j) Representative immunoblot of the patient-derived gliomasphere line GS187 treated for 7 days with Vehicle, Abemaciclib (CDK4/6 inhibitor), OTX008 (LGALS1 inhibitor), or the combination. Abemaciclib treatment reduced phosphorylation of RB at S780 (pRb) with corresponding effects on total RB, consistent with on-target CDK4/6 pathway inhibition. CCN2A and CDK4 levels are shown as additional markers in the CDK4/6 axis. OTX008 treatment targets LGALS1 and CYPB serves as a loading control. k) Quantification of immunoblot signals shown in panel 4j from GS187 gliomaspheres. Protein levels for pRB (S780), RB, CCN2A, CDK4, and LGALS1 were normalized to the loading control (CYPB) and expressed as fold change relative to Vehicle (dashed line at 1). l) Patient-derived gliomaspheres expressing a Gaussia luciferase construct are transplanted onto human cortical organoids, where tumor cells engraft and secrete luciferase into the surrounding media. Secreted luciferase activity in conditioned media provides a noninvasive readout of tumor cell burden over time. m) Schematic timeline of the treatment regimen used for growth assays in the HOTT system. Following a 7-day engraftment period, organoids transplanted with patient-derived gliomaspheres were treated with Vehicle, Abemaciclib, OTX008, or the combination of OTX008 and Abemaciclib. Conditioned media was collected every 48 hours for measurement of secreted Gaussia luciferase activity, with luminescence quantified to generate tumor growth curves. n) Patient-derived gliomasphere lines GS005 and GS025 (n = 2 independent lines) expressing Gaussia luciferase were transplanted onto human cortical organoids (n = 3 independent transplants per condition) and treated according to the scheme in . Conditioned media were collected every 48 hours and luciferase activity was normalized to the corresponding day 1 measurement for each transplant. Data are shown as mean ± s.d. across independent transplants. Statistical comparisons were performed between drug-treated and vehicle conditions at each time point.

Article Snippet: Organoids were treated with vehicle control (DMSO), abemaciclib (1 μM, MedChemExpress), OTX008 (2.5 μM, MedChemExpress), or a combination of abemaciclib and OTX008 for 7 days, with compounds refreshed at each media change.

Techniques: Expressing, Quantitative Proteomics, Inhibition, Clone Assay, Western Blot, Derivative Assay, Phospho-proteomics, Control, Luciferase, Construct, Activity Assay

Journal: bioRxiv

Article Title: Predictable clonal hierarchies from restricted progenitors provide a framework for cell type-specific therapies in glioblastoma

doi: 10.64898/2026.02.21.707071

Figure Lengend Snippet: Identification of progenitor-associated drug targets with tumor-selective expression a) Strategy used to identify candidate therapeutic targets from lineage-informed progenitor programs. Progenitor signature genes (n = 1,855) were first defined from the CellTagging dataset based on differential expression between progenitor and non-progenitor malignant cells. These genes were queried against the Drug-Gene Interaction Database (DGIdb) to identify targets with known inhibitor interactions, yielding 326 druggable genes. Druggable candidates were then ranked by tumor selectivity using a composite score that integrates progenitor specificity from the CellTagging genescore together with relative expression in a primary GBM meta-atlas and depletion in a normal adult brain meta-atlas, enabling prioritization of progenitor targets with maximal therapeutic window. b) Scatter plot shows progenitor-associated druggable genes identified by querying the Drug-Gene Interaction Database (DGIdb) for inhibitor-linked interactions among progenitor signature genes. The x-axis shows the CellTagging progenitor genescore, a composite metric reflecting both specificity and enrichment in progenitor cells, calculated as the ratio of the fraction of progenitor cells expressing a gene to the fraction of non-progenitor cells expressing the gene, multiplied by the average log 2 fold change. The y-axis shows a tumor-normal score calculated as the difference between z-scored mean expression in a GBM meta-atlas and z-scored mean expression in a normal adult brain meta-atlas. Each point represents a gene. Genes with positive tumor-normal scores (red) are enriched in tumor relative to normal brain, whereas genes with negative scores (blue) show higher relative expression in normal tissue. c) Kaplan-Meier survival curves for proneural GBM patients in the TCGA dataset stratified by LGALS1 expression using a median cutoff. Patients with LGALS1 High tumors (red; n = 81, events = 77, median survival = 11.1 months) exhibit reduced overall survival compared to the LGALS1 Low group (blue; n = 81, events = 58, median survival = 19.8 months). Significance was assessed by log-rank test (p = 3e−04) and Wilcoxon test (p = 5e−04); hazard ratio (HR) = 0.53 (95% CI, 0.38-0.76). d) Volcano plot summarizing differential expression in the primary GBM meta-atlas comparing LGALS1-Low versus LGALS1-High cells. e) Differential expression in the primary GBM meta-atlas comparing LGALS1-Low vs LGALS1-High cells (Low vs High). Each point is a gene (x-axis, avg_log2FC Low vs High; y-axis, −log10 adjusted P value). Positive fold-change indicates genes enriched in LGALS1-Low cells; CDK4 is highlighted/labeled. Differential expression used a Wilcoxon test with min.pct = 0.5 and logFC threshold = 0.25. f) Representative immunoblots from two additional patient-derived gliomasphere lines (GS025 and GS225) treated for 7 days with Vehicle (DMSO), Abemaciclib (1 µM), OTX008 (2.5 µM), or the combination.

Article Snippet: Organoids were treated with vehicle control (DMSO), abemaciclib (1 μM, MedChemExpress), OTX008 (2.5 μM, MedChemExpress), or a combination of abemaciclib and OTX008 for 7 days, with compounds refreshed at each media change.

Techniques: Expressing, Biomarker Discovery, Quantitative Proteomics, Labeling, Western Blot, Derivative Assay

Journal: bioRxiv

Article Title: Predictable clonal hierarchies from restricted progenitors provide a framework for cell type-specific therapies in glioblastoma

doi: 10.64898/2026.02.21.707071

Figure Lengend Snippet: Track-informed combination treatment predictably remodels clonal interaction architecture a) Schematic of the track-informed CellTag lineage tracing and drug perturbation workflow in HOTT. Primary IDH1 WT GBM cells from (n = 3) patient tumors are dissociated and transduced with a high-complexity CellTag lentiviral barcode library encoding combinatorial DNA barcodes and GFP. Barcoded tumor cells are directly transplanted onto human cortical organoids and allowed to engraft and invade toward the organoid center over a 5-7 day period. Following engraftment, organoids are separated and treated with vehicle (DMSO), abemaciclib (1 µM), OTX008 (2.5 µM), or the combination of abemaciclib and OTX008 for 7 days, with drugs refreshed at each media change. At the experimental endpoint, organoids are dissociated and GFP⁺ CellTagged tumor cells are isolated by fluorescence-activated cell sorting (FACS) for single-cell RNA sequencing (scRNA-seq). Lineage relationships are reconstructed by identifying shared CellTag barcode combinations across cells, enabling analysis of treatment-induced changes in clonal architecture. b) UMAP visualization of scRNA-seq profiles from CellTag-labeled GBM cells following treatment in the HOTT (n = 98,474 cells). Cells are colored by treatment condition. c) Fraction of cells assigned to each transcriptional cell type following reference-based mapping from the full CellTag lineage-tracing dataset. d) Clone-member composition shifts (n = 9,138 clones) by cell type following drug treatment. Dot plot shows the log₂ fold change in clone-member representation for each cell type relative to vehicle, computed from unweighted clone-member proportions. For each treatment, the proportion of clone-member cells assigned to each cell type was calculated and normalized to the corresponding vehicle proportion (log₂FC). Dot size represents the magnitude of the log₂ fold change (|log₂FC|), and color denotes directionality (red, enrichment; blue, depletion), with values capped at the 75th percentile. Statistical significance was assessed at the clone level by comparing the distribution of clone-level cell type proportions between each treatment and Vehicle using two-sided unpaired Wilcoxon rank-sum tests, with p-values corrected across all cell type × treatment comparisons using the Benjamini–Hochberg method (**** FDR < 1×10⁻⁴, *** FDR < 1×10⁻³, ** FDR < 1×10⁻², * FDR < 0.05; ns, not significant). e) Top enriched clonal co-occurrence interactions per treatment. For each treatment condition (vehicle, abemaciclib, OTX008, combination), edges represent cell type pairs that co-occur within inferred clones more frequently than expected by chance (log₂ observed/expected), computed from clone × cell type presence matrices. Interactions were filtered to retain pairs with log₂ enrichment ≥ 0.5 and the top 10 strongest enriched pairs per treatment were plotted. Edge thickness denotes log₂ enrichment, and edges are colored by the Track assignment of the recipient cell type. f) UpSet plot of progenitor-progenitor clonal co-occurrence patterns across treatments. Columns denote the top 20 progenitor-progenitor cell type combinations observed within inferred clones; filled circles indicate presence of each progenitor cell type in the combination. The upper bar plot reports intersection size as the fraction of all clones within each treatment exhibiting the corresponding combination, with bars stacked by treatment (vehicle, abemaciclib, OTX008, combination). Fractions are normalized independently within each treatment using the total number of clones in that treatment as the denominator; therefore, stacked bar heights can exceed 100% because per-treatment fractions are summed across conditions. Left bars indicate progenitor set sizes. g) Delta abundance-normalized log₂ enrichment of progenitor-progenitor (PP), progenitor-mature (PM), and mature-mature (MM) cell-cell pairings for each treatment relative to Vehicle. Enrichment values reflect pooled clone-derived cell-cell interactions normalized to overall progenitor abundance. Significance was assessed at the clone level using two-sided Wilcoxon tests with Benjamini-Hochberg correction (* q < 0.05, ** q < 0.01, *** q < 0.001). h) Weighted clone-member Track composition changes relative to Vehicle. Bars show weighted log₂ fold change in Track representation among clone-member cells for each treatment versus Vehicle, with weights defined as 1 / p(Track | Treatment) and baseline Track frequencies computed from all cells. Significance was assessed using clone-level replication (Wilcoxon signed-rank test against 0) with FDR correction (* FDR < 0.05, ** FDR < 0.01, *** FDR < 0.001). i) Clone-level Track interaction residuals for combination treatment. Bars show deviation of the observed Combo effect from the additive expectation of Abemaciclib and OTX008, defined as log₂FC_Combo − (log₂FC_Abemaciclib + log₂FC_OTX008). Residuals were tested against 0 using clone-level replication (Wilcoxon signed-rank test) with FDR correction (* FDR < 0.05, ** FDR < 0.01, *** FDR < 0.001).

Article Snippet: Organoids were treated with vehicle control (DMSO), abemaciclib (1 μM, MedChemExpress), OTX008 (2.5 μM, MedChemExpress), or a combination of abemaciclib and OTX008 for 7 days, with compounds refreshed at each media change.

Techniques: Transduction, Isolation, Fluorescence, FACS, Single Cell, RNA Sequencing, Labeling, Clone Assay, Derivative Assay

Journal: Cancer Communications

Article Title: TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy

doi: 10.34133/cancomm.0009

Figure Lengend Snippet: Timeless down-regulation potentiates erastin combined with anti-PD-1 therapy efficacy. (A) Experimental design for testing the combination of erastin and anti-PD-1 in an orthotopic LLC1 model. Ten days after orthotopic inoculation with 5 × 10 5 shCtrl or shTimeless LLC1 cells, tumor-bearing mice were treated for 20 days with the following regimens: DMSO + IgG2α, erastin (30 mg/kg i.p. daily) + IgG2α, DMSO + anti-PD-1 (200 μg i.p. every 3 days), or erastin + anti-PD-1. (B) Weights of lung tumors after treatment in the orthotopic LLC1 model ( shCtrl and shTimeless : DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1). (C) Mice body weight was monitored every 3 days ( n = 5). (D) Representative TEM images of mitochondria in lung tumors from orthotopic tumor-bearing mice transfected with shCtrl or shTimeless and treated with monotherapy or combination therapy. (E) Bar graphs illustrated the percentage of CD3e + T cells among CD45 + cells, CD4 + T cells among CD3e + T cells, and CD8 + T cells among CD3e + T cells in lung orthotopic tumors. (F) CD86 + (M1-like) and CD206 + (M2-like) macrophage proportions among CD11b + F4/80 + cells in lung orthotopic tumors. (G) Representative mIF images of LLC1 tumor tissues from the shCtrl and shTimeless groups treated with the indicated regimens: DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1. Staining shows Timeless (pink), 4HNE (yellow), Cd4 (purple), and Cd8 (green). Statistical analyses in (B), (E), and (F) were performed using a 2-tailed Student’s t test. Primary comparisons were made between each treatment group and the shCtrl + DMSO + IgG2α control. The significance is denoted above the bars. Further comparisons were conducted between the monotherapy and combination therapy groups, as well as between the shTimeless and shCtrl groups. *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant. Abbreviations: 4HNE, 4-hydroxyonenal; i.p., intraperitoneal; mIF, multiplex immunofluorescence; PD-1, programmed cell death protein 1; TEM, transmission electron microscopy.

Article Snippet: For combination therapy, mice injected with shCtrl and shTimeless LLC1 cells were randomized into 4 groups: (a) DMSO plus isotype IgG2α (BioXcell, Cat. BE0089, 200 μg, injected intraperitoneally on days 10, 13, 16, 19, 22, 25, and 28); (b) erastin (30 mg/kg, injected intraperitoneally daily) plus isotype IgG2α; (c) DMSO plus anti-PD-1 antibody (BioXcell, Cat. BE0146, 200 μg, injected intraperitoneally on days 10, 13, 16, 19, 22, 25, and 28); and (d) erastin plus anti-PD-1 antibody.

Techniques: Transfection, Staining, Control, Multiplex Assay, Immunofluorescence, Transmission Assay, Electron Microscopy